Enterosorbent

 

(57) Abstract:

The invention relates to medicine. Enterosorbent contains microcrystalline cellulose, rosehip extract dry and sorbitol in the following ratio, wt. %: MCC 55-90, rosehip extract dry 5-15, sorbitol 5-30. Enterosorbent further comprises ascorbic acid in an amount of 5-20% and a sugar substitute in an amount of 0.2 to 1.0% by weight of the ICC. Enterosorbent further comprises a liquid extract of Rhodiola rosea in the amount of 1-10% by weight of the ICC. The invention allows to improve therapeutic and prophylactic properties, the taste of the product and to expand the range of tools. 2 C.p. f-crystals.

The invention relates to medicine and can be used as enterosorbent.

Known enterosorbent consisting of microcrystalline cellulose (MCC) "MICROTEL" (registration certificate MOH R 97.128.5, GOS. Register of medicines, M., 2000, s 102).

Cons: unpleasant taste, discomfort of the gastrointestinal tract (constipation).

The invention is aimed at solving problems: improving health care properties and taste of enterosorbent, expansion of the range.

These objectives are achieved is.

In the second option, "Asotin" further includes ascorbic acid in the amount of 5-20% and a sugar substitute in an amount of 0.2 to 1.0% by weight of the ICC.

Part of the third option "Resistin" in addition to option 1 includes an extract of Rhodiola rosea in the amount of 1-10% by weight of the ICC.

Enterosorbent "Microthin" (option 1) is used as a tonic, helps prevent colon cancer, obesity, gall-stone disease and cardiovascular disease.

Enterosorbent "Accosting" (option 2), it is recommended to improve the health of the body's resistance to infections. Enterosorbent "Resistin" (option 3) has advanced restorative properties, is used for fatigue, dystonia, promotes the excretion of toxic substances and products of metabolism.

Enterosorbent is obtained by mixing cells with plant extracts and excipients, followed by pelletizing.

Enterosorbent "Microthin" (option 1) consists of MCC, rosehip extract dry and sorbitol in the following ratio, wt.%:

MKC - to option 1, but contains ascorbic acid and a sugar substitute in the following ratio of components, wt.%:

ICC - 34-84,8

Rosehip extract dry - 5-15

Sorbitol - 5-30

Ascorbic acid - 5-20

The sugar substitute - 0,2-1,0

Enterosorbent "Resistin" (option 3) in addition to option 1 contains liquid extract of Rhodiola rosea in the following ratio, wt.%:

ICC - 45-89

Rosehip extract dry - 5-15

Sorbitol - 5-30

The extract of Rhodiola rosea liquid - 1-10

Examples of specific performance.

Example 1. 90 g MCC mixed with 5 g of rosehip extract dry and add 5 g of sorbitol to form a homogeneous mass. The mixture tabletirujut 0.5 g

Example 2. 55 g MCC mixed with 15 g of rosehip extract dry and add 30 grams of sorbitol to obtain a homogeneous mass. The mixture tabletirujut 0.5 g

Example 3. 84,8 g MCC mixed with 5 g of rosehip extract dried with 5 g of sorbitol, 5 g of ascorbic acid and 0.2 g of sugar substitute until smooth. The mixture tabletirujut 0.5 g

Example 4. 34 g MCC mixed with 15 g of rosehip extract dry, add 30 g of sorbitol, 20 g of ascorbic acid and 1 g of sugar substitute until smooth. The mixture tabletirujut 0.5 g

Example 5. 89 g MCC mixed with 5 g of rosehip extract suhag is S="ptx2">

Example 6. 45 g MCC mixed with 15 g of rosehip extract dry, 30 g of sorbitol and 10 g of an extract of Rhodiola rosea liquid until smooth. The mixture tabletirujut 0.5 g

Enterosorbent "Microthin" (option 1) take 3-4 tablets 2 times a day, a course - 1 month. Take pills for 0.5 hour before meals or after 0.5 hours after meals with water. Children recommend 1/2 dose for adults.

Enterosorbent "Accosting" (option 2) take 2 tablets 2 times a day, the course of 1 month.

Enterosorbent "Resistin" (option 3) take 2 tablets 2 times a day, the course of 1 month.

Clinical examples.

Example 1.

Patient K., 20 years.

Diagnosis: atopic dermatitis, a limited form.

The clinic before treatment: the skin is dry, drain maculata rash on face and chest. The abdomen is soft. Liver +1,5. Chair decorated.

Data from laboratory studies:

OAK before treatment - er 4,2, HB 122, Le 8,3, eosin. 5%.

A smear from a nose on eosinophilia: BC 30%, N. 0%.

The immunological before treatment: General T-lymphocytosis 82%, decrease in humoral - Ig And 0.45, Ig 3,0 G, Ig M 0,70.

Ultrasound of the gastrointestinal tract before treatment: Reactive changes in the liver.

Got Mi is simple, stretchy. The abdomen is soft. Liver a +0.5. Chair decorated.

OAK after treatment - er 4,5, HB 144, Le 7,2, eosin. 1%.

A smear from a nose on eosinophilia: E. 2% N. 5%.

The immunological after treatment: normalizing the total number of T-lymphocytes 60%, the tendency to normalization of T-TFF. 53%, T - TFC. 21% and humoral - Ig 0.9, Ig of 5.7 G, Ig M 1,23.

Ultrasound of the gastrointestinal tract: Normalization of liver size. Morphological changes were not found.

Example 2.

Patient S., Le

The diagnosis of Seborrheic eczema. Intestinal dysbiosis.

The clinic before treatment: the skin is dry behind the ears hyperemia, infiltration, desquamation. Point xerosis across the surface of the skin, erythema of the cheeks with the crusts. Liver and +2.5. Liquid stools 3-4 times a day.

Data from laboratory studies: OAK before treatment - er 4,0, HB 123, Le 7,4, eosin. 8%.

A smear from a nose on eosinophilia: E. 12%, N. 1%.

The immunological before treatment: Leukocytosis 13,4, T-l 54% (upper limit of normal), increased T-active 41%, T-TFF. 69%, T-TFC.(-). The humoral imbalance: Ig A - traces, increasing Ig G - 8,4, Ig M to 0.75. Phagocytosis in normal.

Ultrasound of the gastrointestinal tract before treatment: Liver +3,0. Marked reactive changes in the liver. Reactive pancreatitis.

Analysis of fecal disback Accosting" in a dose of 2 tablets 2 times a day. The course is 1 month.

Clinic after treatment:

The skin stayed dry. The abdomen is soft. Liver +and 1.0. Normalization of stools, 2 times a day, pasty.

OAK after treatment - er 4,1, HB 128, Le 7,0, eosin. 3%.

A smear from a nose on eosinophilia: E. 1% N. 5%.

The immunological after treatment: Le - 8,5 (within normal limits). The trend toward normalization of active E-ROCK - 38%, T-TFF. - 49%, T-TFC. - 10%. The level of Ig And 0,81, Ig of 4.6 G, Ig M 0,89 - normal.

Phagocytosis indices are normal.

The analysis of a feces on a dysbacteriosis: the emergence of bifido-bacteria 104E. coli 1,0108and enterococci 106(in norm), the absence of lactic acid, lactose-negative bacteria.

Ultrasound of the gastrointestinal tract: Liver +and 1.0. Saved reactive changes in the pancreas.

Example 3.

Patient T., 20 years

The diagnosis of dystonia on hypotonic type. Syndrome vegetovisceral dysfunction.

Complaints before treatment: fatigue, weakness, irritability, restless sleep, recurrent headaches, reduced appetite.

The clinic before treatment: Skin is pale, moderate shadows under the eyes, phenomena follicular keratosis. Polyacene. Emotionally labile, short systolic murmur at the apex, diminished in the orthostasis. Tongue coated from root whitish-gray bloom. The abdomen is soft, moderately painful in so well.p., in piloroduodenalnoy area. Liver +0,5 see regular Chair.

Data from laboratory studies: OAK before treatment - er 4,4, HB 132, Le 5,2.

The immunological before treatment: Radiation 4,7, relative T-lymphocytosis in load tests (increased T-TFF., relative - 55%, T-TFC.(-), increased T-stable-44%). The level of immunoglobulins in normal.

Polyreocardiographs study before treatment: increase in total peripheral resistance - 419, reduced cardiac index -1,14 (hypokinetic type of circulation), insufficient hydraulic capacity of 0.2.

Received "Resistin" in a dose of 2 tablets 2 times a day. The course is 1 month.

Complaints after treatment: none.

Clinic after treatment: skin is pale, supple, light shadows under the eyes. Improved appetite and sleep. Decreased symptoms of asthenia. There has been improvement in emotional tone, increase physical activity. The rhythmic heart sounds. Tongue slightly furred at the base. The abdomen is soft, painless. Liver at the edge of the costal arch.

OAK after treatment - CH. - 11%, thermostable E-ROCK - 30%). The content of Ig A, Ig G, Ig M - normal.

Polyreocardiographs study after treatment will increase the total peripheral resistance, normalization pump function (hydraulic power - 0.90) and energy consumption of the myocardium (81,4).

1. Enterosorbent, consisting of microcrystalline cellulose (MCC), characterized in that it additionally contains rosehip extract dry and sorbitol in the following ratio, wt. %:

ICC - 55-90

Rosehip extract dry - 5-15

Sorbitol - 5-30

2. Enterosorbent on p. 1, characterized in that it further comprises ascorbic acid in an amount of 5-20% and a sugar substitute in an amount of 0.2 to 1.0% by weight of the ICC.

3. Enterosorbent on p. 1, characterized in that it further contains an extract of Rhodiola rosea liquid in the amount of 1-10% by weight of the ICC.

 

Same patents:

The invention relates to the processing of larch wood with getting bioflavonoids, specifically dihydroquercetin (DQC), which finds application in medicine, food industry
Enterosorbent // 2180230
The invention relates to medicine
The invention relates to preventive medicine

The invention relates to medicine, namely to radiology

The invention relates to the field of veterinary medicine

The invention relates to radiation biology and experimental medicine, namely to radioprotectors of natural origin, the systematic use of which increases the body's resistance to the effects of ionizing radiation
Enterosorbent // 2180231
The invention relates to medicine and can be used as enterosorbent

The invention relates to medicine, namely to dermatology, and can be used in the treatment of eczema and psoriasis

The invention relates to medicine and concerns the establishment of a drug for the treatment of purulent skin infections

The invention relates to medicine and can be used for the treatment of venous leg ulcers

The invention relates to new Bermatingen compounds, the United propylenebis communication, General formula I where Ar represents a radical of formula (a) or (b), R1is-OR6or-COR7, R2represents a polyether radical, comprising 1 to 6 carbon atoms and 1 to 3 atoms of oxygen or sulfur, and if in the latter case, R4represents a linear or branched C1-C20alkyl, he is in ortho - or meta-position relative to X-Ar connection, R3represents lower alkyl, or R2or R3taken together form a 6-membered ring, optionally substituted by at least one of the stands and/or optional split the atom of oxygen or sulfur, R4represents H, linear or branched C1-C20alkyl or aryl, R5represents H or-OR8, R6represents H, R7represents H, -OR10or-N(r)r (r) r are H, lower alkyl or taken together with the nitrogen atom form a ring of morpholino, R8represents H or lower alkyl, R10represents H, linear or branched C1-C20alkyl, X represents a divalent radical, which is from right to left or Vice versa has the formula (d), R11Fri carboxylic acid and the optical and geometrical isomers of the above compounds of formula (I)

The invention relates to medicine

The invention relates to medicine, namely to the treatment of ulcers in the diabetic foot syndrome

The invention relates to medicine, to compositions for skin care containing 0.001 to 10.0% of retinol or its ether complex, 0,0001-50.0% inhibitor reaction of esterification of retinol (N-substituted fatty acid amide) and the media
The invention relates to medicine, to surgery, to a method of treatment of fistulous dermatitis
The invention relates to medicine, in particular to plastic surgery, and can be used for the treatment of burn wounds
The invention relates to medicine, in particular to pharmacology relates to a dry powder composition containing budesonide and substance-media, which are finely dispersed form, and the drug has a loose bulk density of from 0.28 to 0.38 g/ml, and also relates to a method of obtaining a composition and method for the treatment of respiratory disorders
The invention relates to medicine, in particular to the drug for inhalation, representing a dry powder composition comprising the terbutalina sulfate and substance-media, which are finely dispersed form, and the drug has a loose bulk density of 0.28 - 0,38 g/ml and is useful in the treatment of respiratory disorders, as well as gives superior dispersion drugs

The invention relates to medicine, Hepatology, to methods of treatment of chronic viral hepatitis
Up!